TCS-OX2-29 is an orexin antagonist. It was the first non-peptide antagonist developed that is selective for the orexin receptor subtype OX2, with an IC50 of 40nM and selectivity of around 250x for OX2 over OX1 receptors.[1] Orexin antagonists are expected to be useful for the treatment of insomnia, with subtype-selective antagonists such as TCS-OX2-29 potentially offering more specificity of action compared to non-selective orexin antagonists like almorexant.[2]
Identifiers | |
---|---|
| |
CAS Number |
|
PubChem CID |
|
IUPHAR/BPS |
|
Chemical and physical data | |
Formula | C23H31N3O3 |
Molar mass | 397.519 g·mol−1 |
3D model (JSmol) |
|
| |
(verify) |